Enhanced FDA Compliance Program Inspections Will Directly Impact the Approval of HLB's Riboceranib for Liver Cancer.
FDA's Modernized Compliance Program and Data Integrity
The U.S. Food and Drug Administration (FDA) is tightening regulations by significantly revising its Compliance Program Guideline Manual (CPGM), which outlines the agency's standards for drug quality control, including Chemistry, Manufacturing, and Controls (CMC) and on-site inspection guidelines. In particular, during the regulatory enforcement process from 2025 to 2026, preventing the misuse of artificial intelligence (AI) and ensuring data integrity will be key audit items. This signifies the regulatory authority's commitment to monitoring the entire process, from the generation to the disposal of raw data in the manufacturing process, beyond simply verifying figures on paper. This standardized monitoring system creates an environment where even clinically proven new drugs can be rejected due to minor flaws in the manufacturing process.
HLB and Hengrui Pharmaceutical's Repeated CMC Challenges and the Journey of Riboceranib
HLB (028300), a leading Korean bio company, and its partner, Jiangsu Hengrui Pharmaceuticals (600276), have also struggled to overcome these regulatory hurdles. The two companies applied for approval of a combination therapy of riboceranib and camrelizumab for the first-line treatment of unresectable hepatocellular carcinoma (uHCC), but received two Complete Response Letters (CRLs) in May 2024 and March 2025. Although there were no issues with the drug's clinical efficacy, the FDA's compliance program standards were not met during the CMC inspection of Hengrui Pharmaceutical's manufacturing facility. On January 2026, they completed the resubmission of documents (NDA/BLA Resubmission) and embarked on their third attempt.
PDUFA Target Date and On-Site Inspection (CGMP) Variables
The FDA's Prescription Drug User Fee Act (PDUFA) sets the final review date for August 23, 2026, drawing significant market attention. Industry concerns are focused on the fact that, as of one month before the review deadline, the FDA has not yet announced a schedule for an official reinspection of Hengrui Pharmaceutical's production facilities. Typically, an additional on-site inspection to verify that the deficiencies have been addressed is essential, but recently, the FDA has been using a combination of remote interactive evaluations and unannounced inspections. The regulatory agency's choice of method will determine whether the final approval date is further delayed or whether immediate approval is granted, heightening investor anxiety.
Competitive Landscape and Commercial Value of the First-Line Liver Cancer Treatment Market
If the combination therapy of riboceranib and camrelizumab passes the regulatory hurdles, it will enter the global first-line hepatocellular carcinoma market, which is expected to grow to USD $7.5 billion annually. Currently, this market is dominated by Roche's combination therapy of Tecentriq and Avastin, and AstraZeneca's combination therapy of Imfinzi and Imjudo. HLB's riboceranib combination is preparing to compete directly with these therapies, based on its excellent overall survival (mOS) data, and has completed the establishment of a sales network across the United States through its subsidiary, Elevar Therapeutics.
The FDA's stricter CGMP and data integrity verification approach in its compliance program demonstrates that manufacturing process stability, as well as clinical value, is a key variable in new drug development. If HLB (028300)'s riboceranib and camrelizumab combination therapy is approved by the August 23, 2026, PDUFA date, the two companies will be able to disrupt the oligopolistic structure of the USD $7.5 billion annual market for unresectable hepatocellular carcinoma (uHCC) first-line treatment. This will lead to a full-fledged competition for market share with existing standard-of-care therapies such as Roche's Tecentriq + Avastin and AstraZeneca's Imfinzi + Imjudo, which is expected to cause a shift in the market landscape in the medium to long term. On the other hand, if the CMC issues are not resolved in this third review, it will inevitably lead to financial losses due to delays in global commercialization, as well as a decline in confidence in the FDA regulatory response capabilities of Asian bio companies. Therefore, the enhancement of pharmaceutical regulatory compliance processes has become a strategic imperative that determines the survival and return on investment of the entire pharmaceutical and bio industry, beyond the research and development stage.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-compliance-programs